ArticleScientific reports2026
Spared cognitive and social function following perinatal ablation of ATRX despite transient microglia dysregulation.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Mutations in the chromatin-remodelling factor ATRX cause syndromic intellectual disability (ID) and autism spectrum disorder (ASD), but the role of microglial ATRX in early brain development remains poorly understood. Here, we used a tamoxifen-inducible Cx3cr1-CreERT2 system to delete Atrx specifically in microglia during the first postnatal week. High recombination efficiency was achieved by one month of age; however, knockout efficiency declined by three months to approximately 20% in the cortex and 40% in the hippocampus, suggesting repopulation by wild-type microglia. ATRX-deficient microglia exhibit an increase in CD68-positive foci, greater ramification complexity, and enlarged cell volume, consistent with a reactive phenotype. Furthermore, we observed an elevated proportion of Ki67-positive proliferative microglia at both one and three months of age. To assess the functional consequences of these cellular alterations, we evaluated juvenile and adult ATRX microglial knockout (mi-KO) and control mice across a behavioural battery assessing anxiety-like behaviour, locomotion, learning and memory, social interaction, and sensory gating. No significant genotype-dependent differences were detected across these domains. Together, these findings indicate that perinatal loss of ATRX in microglia induces a reactive phenotype and turnover without measurable impacts on neurobehavioural outcomes, suggesting developmental resilience of neural circuits to transient microglial dysregulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.